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Abstract 
Patients with mild bleeding disorders (MBDs) are under-recognised and frequently present 
to general physicians. The underlying reasons for bleeding are multifactorial. There is little 
in the way of evidence to guide diagnostic and management decision making in patients 
with MBDs.  
 
Here we outline different types of MBDs, paying particular focus to bleeding associated with 
low von Willebrand factor levels and mild platelet defects. We give practical, evidence 
based advice on the investigation and management of patients with a suspected or known 
MBD, considering the scenarios of an acute bleed, stable outpatient, peri-surgical 
management and thrombosis. 
 
Patients with an MBD have variable bleeding due to the interplay of genetic and 
environmental factors. The clinical history remains of utmost importance in their general 
management. Liaison with a specialist centre, multidisciplinary assessment and a careful 
judgement of the balance of risk in each individual circumstance is required to safely 
manage these patients. 
 
Keywords 
Bleeding; Coagulation; Haemostasis; von Willebrand’s Factor; Platelets; Mild Bleeding 
Disorders 
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 The majority of mild bleeding disorders (MBDs) are acquired. 
 Clinical history is the most important part of an assessment of a patient with a 
known or suspected MBD. 
 An individual patient’s bleeding phenotype for any given MBD is variable due to the 
complex interplay of genetic and environmental factors. 
 Laboratory testing is not always diagnostic or informative in a patient with an MBD. 
 Close liaison with a haematologist is recommended in managing patients with MBDs. 
 
 
Introduction 
Patients with severe bleeding disorders are usually diagnosed early in life, especially when 
there is a family history of excessive bleeding in which case diagnosis can be made in the 
neonatal period or in some cases antenatally.  Patients with severe bleeding disorders are 
managed by specialist centres (referred to as haemophilia centres, although they manage a 
variety of bleeding conditions) with clear management plans in place in the event of 
bleeding episodes presenting to non-specialist centres. It is far more likely, however, for a 
general physician to come across a patient with symptoms of mild bleeding. In this review, 
we propose to define what is meant by mild bleeding and outline the underlying causes, 
how these patients typically present, how they should be investigated and managed by 
general physicians and if and when specialist referral is appropriate. Severe bleeding 
disorders are well characterised and will not be discussed further here other than to use 
them for comparison. 
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Typically, patients with mild bleeding disorders (MBDs) present to clinicians in adulthood 
after haemostatic challenges, such as dental surgery or traumatic injury, which result in a 
bleeding episode(s) considered to be unusually severe. Women often present earlier than 
men because menstruation and childbirth provide significant haemostatic challenges.  It is 
common for patients to have had numerous episodes of disproportionate or excessive 
bleeding prior to an inherited bleeding disorder being considered as a possible cause. 
 
Major bleeding has been previously defined as; symptomatic bleeding into a critical area 
such as the brain or spinal cord; bleeding which causes a reduction in Haemoglobin of ≥ 20 
g/l or requires transfusion of ≥ 2 units of packed red cells; or bleeding causing death1. For a 
bleeding disorder to be classified as severe, it has to result in spontaneous major bleeding 
such as haematomas, haemarthroses, CNS, GI and umbilical cord bleeding2. An MBD by 
contrast, is often difficult to tease apart from bleeding symptoms experienced by normal 
individuals. Various studies have attempted to define what are normal rates of bleeding in 
healthy people3. The frequency of spontaneous or provoked bleeding symptoms in the 
general population varies between 3 – 26% depending on study and type of bleeding, with 
one study reporting 73% of those questioned having had one bleeding symptom and 43% 
two symptoms4. The bleeding patterns of those diagnosed as having an MBD can be very 
similar to this5, hence a standardised method of assessing bleeding has been developed by 
the International Society on Thrombosis and Haemostasis (ISTH) called the Bleeding 
Assessment Tool (ISTH BAT). It was specifically designed to capture mild recurrent bleeding 
that may have been missed by previously used scoring systems. It comprises assessment of 
14 bleeding symptoms with each being graded as 0-4 based on the worst bleeding event of 
that type ever experienced by the patient. Results are considered abnormal if ≥4 for men, 
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≥6 for women and ≥3 for children6. It has been validated for von Willebrand’s Disease (vWD) 
and platelet defects7,8 in adults and children but not for haemophilia or rarer bleeding 
disorders such as fibrinogen deficiency or factor XIII deficiency. We will further discuss its 
use and limitations in MBDs below. 
 
Once patients have been diagnosed with a bleeding disorder, the UK Haemophilia Centre 
Doctors’ Organisation (UKHCDO) and NHS England guidance dictates that patients should be 
registered with a Comprehensive Care Centre (CCC) with care provided by consultants, 
specialist nurses and specialist physiotherapists trained in the treatment of patients with 
haemophilia and other bleeding disorders. The CCC will then link in with a more local 
Haemophilia Centre (HC) and coordinate the patient’s care between them to include 24 
hours a day, 7 days a week care, including protocols for out-of-hours care and emergency 
management as well as routine outpatient review 9. This guidance applies to MBDs as well 
as severe bleeding disorders. 
 
Different Types of Bleeding Disorder 
Causes of bleeding disorders can be broadly split into those that affect the coagulation 
cascade, those that affect platelet number or function and those that cause problems with 
the vasculature. The causes of MBDs can be classified in the same way but, with some 
exceptions which will be discussed later, this is not always clinically useful as treatment is 
often generic10 and is based on the clinical bleeding phenotype rather than the underlying 
diagnosis. It is probably more helpful to view the disorders illustrated below as risk factors 
for bleeding rather than causes. This is in much the same way that smoking status, cancer or 
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recent trauma are considered risk factors for thromboembolic disease rather than the 
underlying cause5.  
 
Acquired mild bleeding disorders are much more common than their hereditary 
counterparts and thus the former will be the focus for this review. A table summarising the 
different underlying pathologies associated with MBD is included for reference (Table 1).  
 
Disorders of the coagulation cascade 
Vitamin K antagonists (VKAs) and Direct Oral Anticoagulants (DOACs) induce bleeding 
through reduction of vitamin K dependent clotting factors II, VII, IX and X or inhibition of 
Factors X / II respectively11. There are existing extensive reviews of management of patients 
taking these drugs and therefore they will not be covered in detail. 
 
Dietary deficiency of Vitamin K is common, particularly in long term hospital inpatients. It 
results from poor intake of vitamin K rich foods, such as spinach, from changes in 
gastrointestinal bacteria due to antibiotics, or due to fat malabsorption. The most common 
clinical sequaelae are mild prolongation of the Prothrombin Time (PT), or an increased 
sensitivity to warfarin, but it only rarely results in in excessive bleeding12. 
 
Inherited coagulation factor deficiencies generally cause a severe bleeding disorder or are 
very rare. The commonest inherited bleeding disorder is vWD with quoted rates as high as 
1.3% in the general population. There are several subtypes of vWD which are classified 
based on measurements of von Willebrand Factor (vWF) level, activity and interactions with 
platelets. The bleeding phenotype varies based on the subtype13. It is important, however, 
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to distinguish between vWD and a disorder called “Bleeding with low vWF as a risk factor”. 
The reportedly high rates of vWD are probably an over estimate. They are based on an 
Italian study14 where 1200 children and their relatives were questioned to see if they had 
bleeding symptoms. All 47 people found to have low vWF levels were then followed up for 
13 years and only one person had a clinically significant bleeding event in that time, 
implying that people incidentally found to have low vWF levels should not be labelled as 
having VWD because they are unlikely to have a bleeding event. There is not always a direct 
inverse relationship between bleeding score and laboratory parameters used to assess VWD 
(Lester W, unpublished data, personal communication), although some papers have shown 
a correlation in large patient populations15. These findings reiterate that clinical and family 
history is of paramount importance in assessment and in deciding which patients should 
have laboratory investigations. Although historically levels of VWF <0.5 iU/ml are 
considered to be the cut off for normal, recent guidelines suggest that a cut off level of 0.3 
iU/ml should be used to diagnose vWD. Patients with bleeding and vWF levels of 0.3-0.5 
iU/ml should be labelled as having a “bleeding disorder with low vWF as a risk factor” rather 
than vWD. It is noteworthy that a diagnosis of vWD carries with it many implications such as 
not being allowed a career in the armed forces. 
 
Factor XI deficiency is noteworthy because it is one of the more common inherited bleeding 
disorders and has very heterogenous bleeding. There is very poor correlation between the 
factor level and the bleeding phenotype16 and this presents some treatment challenges. 
 
Factor XII deficiency does not cause any bleeding, but does cause prolongation of the 
activated partial thromboplastin time (APTT). Its diagnosis commonly results from routine 
 7 
clotting screens being performed prior to invasive procedures. The finding of a prolonged 
APTT invariably causes delays to these procedures but no other clinical sequelae. It is 
included here as an example of why clotting screens should only be performed on patients 
who have a history of excessive bleeding or a positive ISTH BAT.  
 
Other disorders of the coagulation cascade which can cause mild bleeding include liver 
disease. This causes bleeding because of loss of production of the procoagulant clotting 
factors and clotting screens such as the PT and APTT can be used as a proxy measurement of 
their loss. Unfortunately the clotting times measured by these tests do not correlate well 
with bleeding because they do not take into account the presence or absence of the 
anticoagulant proteins, also produced by the liver, such as protein C, protein S and 
antithrombin, or platelet abnormalities.  There is still much discussion in the literature as to 
the best method to use to measure the bleeding risk in patients with liver disease17. 
 
Disorders of platelet number / function 
There are numerous rare inherited disorders of platelet function with eponymous names 
that are well known. Those that cause MBD are far less well known and include problems 
with the platelet cytoskeleton such as the MYH9 related disorders or with secretion of 
platelet granules such as with Wiskott Aldrich and Hermansky Pudlak syndromes. As well as 
bleeding, these conditions are associated with other systemic features such as deafness, 
nephropathy and early cataracts (MYH9); eczema and immunodeficiency (Wiskott Aldrich); 
or oculocutaneous albinism, colitis and pulmonary fibrosis (Hermansky Pudlak)18. 
Abnormalities in the platelet ADP receptor P2Y12 also cause MBD. An acquired deficiency of 
P2Y12 signalling occurs with the antiplatelet drugs clopidogrel, prasugrel and ticagrelor 
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which cause major bleeding at rates of between 3 and 12% in different studies19. Of note 
clopidogrel and prasugrel (as well as aspirin) are irreversible platelet inhibitors and thus 
their effects on bleeding last for the lifetime of the platelet (i.e. 7-10 days after clearance of 
the drug). Eptifibatide, tirofiban and abciximab are used for the treatment of acute 
myocardial infarction. They inhibit the platelet fibrinogen receptor GPIIb / IIIa which 
normally functions to strengthen clots by allowing fibrinogen cross-linking to occur between 
platelets. They are all associated with bleeding20-22 and, in addition, abciximab can cause a 
temporary immune mediated thrombocytopenia.  
 
Renal failure’s association with haemostatic problems is multifactorial with the most 
significant effects being through impaired platelet granule secretion23 and problems with 
platelet interaction with the vessel wall through low levels of platelet receptors GPIb and 
GPIIb/IIIa (VWF and fibrinogen receptors respectively). As well as causing coagulation factor 
deficiencies, liver disease also causes reduction in platelet number (previously thought to be 
merely due to sequestration in the enlarged spleen but now known to be due to multiple 
mechanisms) and also in platelet function through activation of inhibitory pathways within 
platelets24. 
 
Immune Thrombocytopenia (ITP) is a heterogenous disorder with a very variable bleeding 
(and sometimes pro-thrombotic25) phenotype, which is not well correlated with the 
absolute platelet count. There are extensive guidelines on diagnosis and management of 
patients with ITP26. It will not be covered any further here.  
 
Disorders of the vasculature 
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Problems with the vasculature impair haemostasis and cause MBD through increased vessel 
fragility27 and weakness resulting from defects in the supportive tissue of blood vessels 
(Ehlers Danlos Syndrome, Scurvy28 and Marfan’s27 syndrome) or defects in the blood vessels 
themselves (Hereditary Haemorrhagic Telangiectasia (HHT)29). 
 
Practical advice on the investigation and management of a patient presenting with mild 
bleeding 
In managing patients with an MBD, we will discuss several scenarios that the general 
physician is most likely to encounter. Broadly, this will be divided into patients with a 
suspected diagnosis and those with a known MBD. A key point is the difficulty in making 
specific recommendations; MBDs by their nature have a variable bleeding phenotype, often 
with an unknown risk, and the range of scenarios is substantial. In most cases, a balanced 
discussion of bleeding risk both from the patient’s underlying condition and as a result of 
any medical or surgical procedure between the patient, haematologist and relevant 
specialty is essential.  For elective procedures this discussion should occur well in advance of 
the planned date to allow a treatment plan to be documented and circulated amongst the 
various teams involved. 
 
The patient with a suspected MBD 
In this scenario, there are several aspects that should be considered. In the emergency 
situation the critical point to stress is that life and limb saving procedures should continue 
regardless of the bleeding phenotype. Most MBDs are amenable to relatively conservative 
measures for control, and on these occasions proceeding as for a patient with no bleeding 
disorder would be a potential option. The area where bleeding risk should be seriously 
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considered is where uncontrolled bleeding can have a catastrophic effect – the classic 
scenario being a neurosurgical procedure. 
 
It is important to try and establish how significant a bleeding history the patient has. In a 
significant proportion of patients, this can be established through close enquiry about 
haemostatic challenges30. Whilst the ISTH BAT is useful as a research tool, it is cumbersome 
for routine use. It is useful to ask whether the patient has had previous surgery. If so, did 
they require added measures, blood product transfusion or a return to theatre because of 
bleeding? Common procedures that can suggest a bleeding disorder include dental 
extraction and tonsillectomy. In addition, a family history can be suggestive, and this should 
be sought specifically if a patient mentions a bleeding tendency. In women, menorrhagia 
since menarche is suggestive30. A potential pitfall is asking about post-partum haemorrhage 
(PPH) as pregnancy itself causes the patient to become prothrombotic, MBDs may very well 
be masked close to delivery. However, repeated PPH without an obvious obstetric cause can 
be suggestive. A summary of useful questions and investigations that can be used in order 
to identify a patient with a potential MBD is given in Table 2. 
 
As a minimum, these patients should have a full blood count and blood film, a PT, APTT, 
Fibrinogen level (usually Clauss fibrinogen), and renal and liver function requested. These 
tests have a short turnaround time, are more useful in the context of a patient with a high 
pre-test probability of a bleeding tendency, and can identify a subset of acquired and 
congenital bleeding disorders. Beyond this, liaison with a haematologist is recommended to 
consider further testing, for example for vWF antigen and activity. 
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Acute management of bleeding  
As with any patient with bleeding, it is important not to forget general supportive measures. 
Resuscitation should proceed as per standard care with a view to control haemorrhage 
using appropriate techniques, be this with direct pressure, endoscopy, interventional 
radiology or open surgery. Often, in a suspected MBD, tranexamic acid (TxA) can be used 
empirically as an intravenous bolus (discussed in greater detail below). Liaison with a clinical 
haematologist can facilitate laboratory testing, and if bleeding is not responding to standard 
measures, some of the empirical options mentioned below may be considered. 
 
Emergency invasive procedures 
As with a significant bleed, if a patient requires limb or life saving surgery this should not be 
delayed for a full work up of an MBD. The key point is to weigh up the risk of the procedure 
against the risk of bleeding, and this can often lead to discussion with multiple specialties. 
Consideration of alternative strategies, or possibly deferring a procedure will depend on the 
individual situation. For example, in a patient with a possible subarachnoid haemorrhage 
and a suspected MBD, earlier recourse to CT angiography with digital subtraction imaging 
may be considered before a lumbar puncture to examine for xanthochromia.   
 
Elective procedures 
In general, with an elective procedure, we would recommend an initial discussion with a 
haematologist followed by a referral for comprehensive assessment. Although the timescale 
to investigate and register a patient for an MBD will depend on the individual centre, most 
units will be able to perform a clinical risk assessment depending on the type of surgery and 
the urgency in an appropriate timeframe.  
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Thrombosis 
The management of arterial and venous thrombosis in patients with an MBD is a complex 
area with no standardised guidance. Due to the multiple factors that determine a person’s 
tendency to bleed or develop thrombosis, collecting enough data for individual MBDs 
presents a challenge. If a patient with an MBD develops thrombosis, we would advocate a 
review of the bleeding history, and a careful discussion involving the patient, haematologists 
and the relevant specialty managing the thrombosis. In general, a trial of standard care 
would be considered, with patient education regarding the risks and signs of bleeding. 
However, in circumstances where the bleeding is significantly worsened by antiplatelet or 
anticoagulant treatment, a review for exacerbating factors would be necessary, with 
consideration for either a trial of an alternative agent or a dose reduction. 
 
The patient with a known MBD 
In this scenario, as with the unknown patient, it is important to stress that the management 
of life and limb threatening emergencies should not be delayed. The patient will usually be 
known to a CCC, and may carry a card with their diagnosis. Patients with a known MBD can 
vary significantly with regards to their knowledge of their disorder. By definition, an MBD 
suggests that it is less likely to affect the patient day to day and so some patients may not 
ascribe significance to the diagnosis. 
 
If a patient is registered with a CCC, liaison with the specialist team is advised at the earliest 
opportunity. In these circumstances the department will have a record of the severity of the 
bleeding disorder and a suggested protocol for management. The haematologist is likely to 
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suggest a course of action depending on the individual scenario. Potential options can 
include: 
 
Trial of procedure 
If the MBD is considered significantly mild, and the surgery is relatively low risk for bleeding, 
the procedure can go ahead with minimal intervention. This is often used with superficial, 
soft tissue procedures, i.e. where bleeding is likely to be simple to control. In some 
circumstances, a trial of procedure can be advised with adjunctive treatment on standby. As 
a comparison, there are various guideline recommendations as to which procedures can 
proceed as normal in patients receiving antiplatelet and anticoagulant therapy31. Ultimately, 
the operator is best placed to assess bleeding risk of the procedure, and should document 
this discussion with the patient and haematologist. 
 
Tranexamic acid 
TxA is a synthetic lysine analogue that inhibits fibrinolysis through competitive binding of 
plasminogen. It is on the World Health Organisation’s list of essential medicines32, and has 
been licenced for menorrhagia, epistaxis and dental extraction in haemophilia, and more 
recently in any massive trauma and PPH33,34. It can be administered intravenously or orally 
prior to a procedure, and is usually continued for several days afterwards. Although there is 
a theoretical risk of thrombosis, this has not been borne out in large clinical trials33,34. The 
main contraindications to consider are haematuria (where there is a risk of clot retention) 
and disseminated intravascular coagulation.  
 
Desmopressin 
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This synthetic derivative of antidiuretic hormone has been licenced for use in mild to 
moderate haemophilia and vWD. The mechanism of action is through the release of stored 
vWF and factor VIII from the subendothelium, with a peak action 90-120 minutes after 
subcutaneous or intranasal administration35. Although doses can be repeated at 12 hourly 
intervals, tachyphylaxis can occur due to acute reduction in subendothelial vWF stores. The 
medication is contraindicated in unstable angina and heart failure, and the patient and 
physicians should be made aware of the risk of fluid overload. Desmopressin should also be 
used with caution in elderly patients, because of the rarely reported increased risk of 
precipitating cardiac ischaemia36.    
 
Platelet transfusion 
This is rarely used in the context of an MBD. Use of meticulous haemostasis, TxA and 
desmopressin are often sufficient for most contexts. In the patient with a platelet disorder 
and a high-risk procedure, transfusion of a single unit of platelets may be considered as a 
way of temporarily overcoming the defect37. In this scenario, the platelet transfusion should 
be given immediately pre-procedure. 
 
Plasma and plasma derived products 
The use of fresh frozen plasma in MBDs is very limited, and generally avoided due to lack of 
efficacy and associated risks. The same is true for cryoprecipitate, and prothrombin complex 
concentrate. Indications for the use of these products are beyond the scope of this review, 
though are well established38. 
 
Conclusions 
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Patients with an MBD represent a unique clinical challenge, and can present to any 
specialty. Whilst the mechanism for a significant number of MBDs can be identified, the 
phenotype remains variable due to the interplay of genetic and environmental factors. In 
addition, testing for individual MBDs requires expertise to perform and interpret. For these 
reasons, the clinical history remains of utmost importance in the general management of 
these patients. The nature of these conditions means that liaison with a specialist centre, 
multidisciplinary assessment and a careful judgement of the balance of risk in each 
individual circumstance is required to safely manage these patients. 
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Table 1. Classification of mild bleeding disorders 
Type of Disorder Hereditary / Acquired Disorder 
Disorders of Coagulation 
Cascade 
Acquired Drugs: VKAs + DOAC’s 
Dietary Vitamin K Deficiency 
Liver Disease 
 Hereditary Mild haemophilia A+B 
Some types of vWD 
Bleeding with low VWF as a risk factor 
Factor XI deficiency  
Disorders of platelet 
number / function 
Acquired Drugs: Aspirin, P2Y12 inhibitors, 
GPIIb/IIIa inhibitors  
Renal and Liver Disease 
ITP  
 Hereditary MYH9 related disorders 
Wiskott-Aldrich syndrome 
Hermansky Pudlak syndrome  
Disorders of the vasculature Acquired Vitamin C deficiency  
 Hereditary  Ehlers Danlos syndrome  
HHT and other vascular malformations 
Marfan’s syndrome 
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Table 2. Identifying a patient with a potential MBD 
Key features for identifying a potential MBD 
Key questions in identifying an MBD 
 Has there been any significant bleeding after surgical or dental procedures? 
 Has this resulted in a return to theatre or unexpected blood transfusion? 
 Is there a family history of increased bleeding tendency? 
 In female patients, is there a history of menorrhagia since menarche, or repeated 
PPH with no clear obstetric cause? 
 Is the patient taking any antiplatelets or anticoagulants? 
Baseline investigations 
 Full blood count and blood film 
 PT, APTT, fibrinogen 
 Renal and liver function 
 
Table 3: Procedures with published low bleeding risk 
Procedures with published guidance on safety with antithrombotic treatment 
Simple dental procedures 
Joint injections 
Cataract surgery 
Pacemaker insertion 
Diagnostic endoscopy with biopsy 
Biliary or pancreatic stenting 
Cholecystectomy 
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